TAIWAN BIO THERAPEUTICS INC.
Update：2026/11/10
Industries
Main Industry
Biotechnology
Main Product/Service
Leveraging the FAST CGT platform to enhance the specificity, persistence, and stability of regulatory T cells, improving their ability to restore immune tolerance and suppress inflammation as a targeted alternative to non-selective, high-risk immunosuppre
The content above was translated by Ai
Founded Year
2014
Unified Business No.
24571303
Status
Active
Number of Employees
0
Total Paid-in
Capital
940,152,280 (NT$)
Location of Company
Taiwan
, Hsinchu County
Exit Status
Emerging Stock Exchange(2025)
Company names, registration status, legal representatives, founding years, paid-in capital, registered addresses, and other details are sourced from business registration records maintained by Taiwan’s Administration of Commerce, Ministry of Economic Affairs. Exit status includes Emerging Stock Board listings, M&A, and IPOs. Information on overseas expansion is self-reported by startups.
Note 1: FINDIT compiles company information from public and other sources for reference and does not serve as a point of contact for the companies listed.
Note 2: Some company profiles and product/service descriptions are translated using AI and provided for reference only. In case of discrepancies or ambiguity, the original text prevails.
Exclusive content for members
Members-only content. Please log in to access.
About the Company
Taiwan Bio is dedicated to driving innovation and expanding access to cell therapies. Through our FAST CGT platform, we reduce costs, enhance efficacy, accelerate development, and streamline production, setting new milestones in the treatment of chronic and immune-related diseases. Originating in Taiwan, our technology is now expanding globally through strategic collaborations with leading U.S. universities and research institutions, fostering a robust cell therapy ecosystem.
The content above was translated by Ai
